# Dave Mullarkey

> Dave Mullarkey is the CEO of ClearNote Health, a San Diego company that reads the chemical edits on your DNA to catch deadly cancers before symptoms show. A life-sciences operator who has shepherded three diagnostics and sequencing companies through scale-ups and acquisitions - Ariosa to Roche, Omniome to PacBio - he now leads the team behind the Avantect epigenomic blood tests for pancreatic and multi-cancer detection.

- **Role:** Chief Executive Officer at ClearNote Health
- **Organizations:** ClearNote Health, Bluestar Genomics, Omniome, PacBio, Ariosa Diagnostics, Roche Sequencing Solutions, Johnson & Johnson, Eli Lilly and Company, Valeant Pharmaceuticals, Dow Pharmaceutical Sciences
- **Nationality:** American
- **Education:** BS, Applied Economics and Management, Cornell University, Charles H. Dyson School of Applied Economics and Management, MBA, Northwestern University, Kellogg Graduate School of Management
- **Known for:** Led Ariosa Diagnostics through rapid global growth to its 2014 acquisition by Roche, Guided Omniome from early-stage technology to beta prototype and its 2021 acquisition by PacBio, Rebranded Bluestar Genomics as ClearNote Health and shifted it into commercial operations

## Career timeline

- **Early career** — Held roles at Johnson & Johnson, Eli Lilly and Company, Valeant Pharmaceuticals, and Dow Pharmaceutical Sciences
- **to 2014** — President and COO of Ariosa Diagnostics, a cell-free DNA non-invasive prenatal testing company, driving global revenue growth
- **2014** — Ariosa Diagnostics acquired by Roche; Mullarkey served as site head and leader within Roche Sequencing Solutions
- **to 2021** — President and CEO of Omniome, scaling the DNA sequencing company from early development to beta prototype
- **2021** — Omniome acquired by PacBio
- **2022-01** — Appointed CEO of Bluestar Genomics
- **2022-12** — Bluestar Genomics rebrands as ClearNote Health and enters commercial phase
- **2026-05** — ClearNote Health secures $52 million Series D financing and strengthens leadership team

## Achievements

- Led Ariosa Diagnostics through rapid global growth to its 2014 acquisition by Roche
- Guided Omniome from early-stage technology to beta prototype and its 2021 acquisition by PacBio
- Rebranded Bluestar Genomics as ClearNote Health and shifted it into commercial operations
- Oversaw development and commercialization of the Avantect pancreatic cancer test
- ClearNote's Avantect multi-cancer detection test selected for the National Cancer Institute's Vanguard study
- Raised a $70M Series C (2021) and a $52M Series D (2026) for ClearNote Health

## Latest updates

- **2026-05** — ClearNote Health secured $52 million in Series D financing and strengthened its leadership team to accelerate growth in early cancer detection.

## Links

- Website: https://clearnotehealth.com
- LinkedIn: http://www.linkedin.com/in/dave-mullarkey
- Twitter/X: https://twitter.com/ClearNoteHealth

---

Profile page: https://yespress.io/dave-mullarkey
Published by YesPress — https://yespress.io
Last updated: 2026-06-13